Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-cash Items (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Non-cash Items for 7 consecutive years, with $775000.0 as the latest value for Q4 2022.

  • On a quarterly basis, Non-cash Items changed N/A to $775000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $775000.0, a N/A change, with the full-year FY2022 number at $775000.0, changed N/A from a year prior.
  • Non-cash Items was $775000.0 for Q4 2022 at Theravance Biopharma, down from $1.2 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $8.5 million in Q4 2019 to a low of $775000.0 in Q4 2022.
  • A 4-year average of $3.9 million and a median of $3.2 million in 2018 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: skyrocketed 66.67% in 2019, then plummeted 85.88% in 2020.
  • Theravance Biopharma's Non-cash Items stood at $5.1 million in 2018, then soared by 66.67% to $8.5 million in 2019, then plummeted by 85.88% to $1.2 million in 2020, then crashed by 35.42% to $775000.0 in 2022.
  • Per Business Quant, the three most recent readings for TBPH's Non-cash Items are $775000.0 (Q4 2022), $1.2 million (Q4 2020), and $8.5 million (Q4 2019).